Synthetic biology will be as diverse a market as AI (multi-trillion)
Predictor: Peter Diamandis · ep#245 "AI + Synthetic Biology: The Most Transformative Technology in Human History | Ben Lamm (Colossal)" · source
Prediction text
Synthetic biology will be as diverse a market as AI (multi-trillion) | you think of AI as a multi multi-t trillion dollar hundred trillion dollar market... Synthetic biology enabled by powered by AI is as big a diverse market.
Verbatim quote
you think of AI as a multi multi-t trillion dollar hundred trillion dollar market... Synthetic biology enabled by powered by AI is as big a diverse market.
Resolution evidence
Peter synbio multi-trillion — abundance thesis, no testable timeframe.
Predictor: Peter Diamandis
Calibration plot (stated vs observed)
Evidence about this node from Peter Diamandis is multiplied by κ in /api/intake. Lower κ = less weight; floors at 0.10 (effectively silenced) and caps at 1.00 (full weight).
Reference class
This node isn't linked to a reference class. The Bayesian update applies without outside-view blending.
Probability over time
Milestone chain
- 2025-12-31partialAI-in-synthetic-biology market reaches $30B in 2025 (CMI estimate)How: Industry research (Custom Market Insights, Grand View, MarketsandMarkets) reports AI-in-synthetic-biology market segment exceeding $30B in 2025 with >25% CAGR forecast.Source: Custom Market Insights — Global AI in Synthetic Biology Market Size, Share 2025-2034conf 70%Notes: PARTIAL — analyst estimates vary widely ($30B/$96.66M reflecting different scoping). Diamandis 'multi-trillion' is far above any 2025 forecast.
- 2027-05-04pendingQ1 window check-in (25%)
- 2026-12-31 → 2028-12-31pendingSynthetic biology total market crosses $50B annual revenueHow: Combined synthetic biology revenue across reagents, services, and end-products (per Mordor / Grand View / Fortune Business Insights) exceeds $50B annual revenue.Source: Mordor Intelligence — Synthetic Biology Market Size, Analysis & Growth Report 2031conf 60%Notes: Required to be on 'multi-trillion' trajectory by 2031.
- 2026-06-01 → 2029-12-31pendingAI-designed protein / molecule receives first FDA new molecular entity approvalHow: FDA grants approval for a new molecular entity (NME) where AI-driven design is the central inventive contribution, per FDA briefing documents or sponsor press release.Source: Anticipated — FDA approval letters, BLA/NDA filingsconf 55%Notes: Required to validate that AI-powered synbio is producing real economic value, not just research output.
- 2028-05-07pendingQ2 window check-in (50%)
- 2029-05-11pendingQ3 window check-in (75%)
- 2027-01-01 → 2031-12-31pendingSynthetic biology firm achieves $100B+ market capHow: A pure-play synthetic biology / AI-bio company (e.g., Ginkgo, Recursion, Schrodinger, Isomorphic Labs, Insitro, or a successor) crosses $100B fully diluted market cap on a public exchange.Source: Anticipated — public exchange filingsconf 30%Notes: Direct equity-market test of 'multi-trillion market' thesis. As of 2026 no synbio pure-play exceeds $20B.
- 2030-01-01 → 2035-12-31pendingSynthetic biology revenue equals 1% of US GDP (~$300B/yr)How: BEA or BLS classifies a 'biofoundry / synthetic biology' NAICS subsector with revenue >$300B annually, comparable to current pharmaceuticals or autos.Source: Anticipated — BEA / BLS NAICS reclassificationconf 20%Notes: Cascade — economic-significance threshold needed to call market 'as diverse as AI'.
What if this resolves?
Click a button to clamp this prediction and run a Gibbs sample. Returns the predictions whose marginals shift most. ~30s per run; ideal for stress-testing "if X resolves, what else moves?"
Evidence chain
Network propagation neighbors
Top incoming (parents)
Edges that influence THIS node's belief
| Kind | Node | Their prob | P(c|s=T) | P(c|s=F) | Δ implied |
|---|---|---|---|---|---|
| killer | TK05 Rate Regime Persistence (10y > 5% through 2028) | 30.0% | 0.050 | 0.650 | -0.082 |
| killer | TK04 Macro Recession 2026-27 (Structural Deleveraging) | 25.0% | 0.050 | 0.650 | -0.052 |
| killer | TK12 Crypto Regulatory Kill Shot (Stablecoin Ban / BTC ETF Revers | 8.0% | 0.050 | 0.650 | +0.050 |
| killer | TK10 $100T Sovereign Debt Crisis | 12.0% | 0.050 | 0.650 | +0.026 |
| killer | TK14 Superbubble Pop (S&P 500 -40%, Moonshot Capital Evaporates) | 20.0% | 0.050 | 0.650 | -0.022 |
Top outgoing (children)
Predictions THIS node influences
No outgoing edges.
Ticker exposure
Beneficiaries (23)
Adverse (5)
Prerequisites (5)
| Type | Pred | Title | Domain | Lag |
|---|---|---|---|---|
| killer | TK05 | Rate Regime Persistence (10y > 5% through 2028) | — | — |
| killer | TK04 | Macro Recession 2026-27 (Structural Deleveraging) | — | — |
| killer | TK14 | Superbubble Pop (S&P 500 -40%, Moonshot Capital Evaporates) | — | — |
| killer | TK10 | $100T Sovereign Debt Crisis | — | — |
| killer | TK12 | Crypto Regulatory Kill Shot (Stablecoin Ban / BTC ETF Reversal) | — | — |
Dependents (0)
| Type | Pred | Title | Domain | Lag |
|---|---|---|---|---|
| No dependents | ||||
Expected milestones (1)
| Expected by | Description | Status |
|---|---|---|
| 2031-03-31 | [Biology 2031-03] [245_042] Synthetic biology will be as diverse a market as AI (multi-trillion) [235_028] Life Biosciences ER-100 Phase 1 first readout (likely late 2026/early 2027) [247_050] Virtual cell achievable through cl | pending |
Raw metadata
{
"nia": false,
"qty": "Multi-trillion to $100T market",
"url": "https://www.youtube.com/watch?v=Goa6c6Qz__I",
"mode": "FORECAST",
"role": "Host",
"context": "you think of AI as a multi multi-t trillion dollar hundred trillion dollar market... Synthetic biology enabled by powered by AI is as big a diverse market.",
"verbatim": "you think of AI as a multi multi-t trillion dollar hundred trillion dollar market... Synthetic biology enabled by powered by AI is as big a diverse market.",
"conv_cues": "as big a diverse market",
"direction": "NUMERIC_TARGET",
"timeframe": "Future",
"conv_level": "HIGH",
"milestones": [
{
"kind": "llm_pre_event",
"label": "AI-in-synthetic-biology market reaches $30B in 2025 (CMI estimate)",
"notes": "PARTIAL — analyst estimates vary widely ($30B/$96.66M reflecting different scoping). Diamandis 'multi-trillion' is far above any 2025 forecast.",
"source": "Custom Market Insights — Global AI in Synthetic Biology Market Size, Share 2025-2034",
"status": "partial",
"weight": 0.4,
"ordinal": -7,
"source_id": null,
"confidence": 0.7,
"source_url": "https://www.custommarketinsights.com/report/al-in-synthetic-biology-market/",
"expected_date": "2025-12-31",
"observed_date": "2025-12-31",
"research_origin": "deep_research",
"measurement_criterion": "Industry research (Custom Market Insights, Grand View, MarketsandMarkets) reports AI-in-synthetic-biology market segment exceeding $30B in 2025 with >25% CAGR forecast."
},
{
"kind": "quartile_checkpoint",
"label": "Q1 window check-in (25%)",
"status": "pending",
"weight": 0.05,
"ordinal": -6,
"source_id": null,
"expected_date": "2027-05-04",
"observed_date": null
},
{
"kind": "llm_pre_event",
"label": "Synthetic biology total market crosses $50B annual revenue",
"notes": "Required to be on 'multi-trillion' trajectory by 2031.",
"source": "Mordor Intelligence — Synthetic Biology Market Size, Analysis & Growth Report 2031",
"status": "pending",
"weight": 0.4,
"ordinal": -5,
"source_id": null,
"confidence": 0.6,
"source_url": "https://www.mordorintelligence.com/industry-reports/synthetic-biology-market",
"expected_date": "2027-12-31",
"research_origin": "deep_research",
"expected_date_range": {
"to": "2028-12-31",
"from": "2026-12-31"
},
"measurement_criterion": "Combined synthetic biology revenue across reagents, services, and end-products (per Mordor / Grand View / Fortune Business Insights) exceeds $50B annual revenue."
},
{
"kind": "llm_pre_event",
"label": "AI-designed protein / molecule receives first FDA new molecular entity approval",
"notes": "Required to validate that AI-powered synbio is producing real economic value, not just research output.",
"source": "Anticipated — FDA approval letters, BLA/NDA filings",
"status": "pending",
"weight": 0.4,
"ordinal": -4,
"source_id": null,
"confidence": 0.55,
"expected_date": "2028-03-16",
"research_origin": "training",
"expected_date_range": {
"to": "2029-12-31",
"from": "2026-06-01"
},
"measurement_criterion": "FDA grants approval for a new molecular entity (NME) where AI-driven design is the central inventive contribution, per FDA briefing documents or sponsor press release."
},
{
"kind": "quartile_checkpoint",
"label": "Q2 window check-in (50%)",
"status": "pending",
"weight": 0.05,
"ordinal": -3,
"source_id": null,
"expected_date": "2028-05-07",
"observed_date": null
},
{
"kind": "quartile_checkpoint",
"label": "Q3 window check-in (75%)",
"status": "pending",
"weight": 0.05,
"ordinal": -2,
"source_id": null,
"expected_date": "2
... (truncated)